Jinsoo Lee

Founded in 2020, Aidenlab is a leading South Korean marketing and beauty company that partners with top local and international brands. We specialize in helping brands expand globally and have a proven track record of setting new industry benchmarks.

At TriOar, our mission is to transform the future of antibody-based therapeutics. Led by a team of highly experienced scientists in the field, our work centers around developing next-generation antibody-drug conjugate (ADC) and immuno-oncology (IO) technologies to solve one of the biggest challenges in oncology: expanding the therapeutic index so that more patients can benefit from novel cancer therapies worldwide. If you share our passion for advancing oncology innovation, let’s connect and explore what we can achieve together.

웰로는 복잡한 정책 정보를 누구나 쉽고 당연하게 누리도록 만드는 Gov-Tech 혁신 기업입니다. 국민과 기업이 당연한 권리를 당연하게 누릴 수 있도록, 정책의 처음부터 끝까지 사용자 중심으로 변화시키고 있어요. 개인 맞춤형 정책 추천 서비스 Wello와 기업 데이터 기반 SaaS WelloBiz를 통해 정책 접근성을 높이고 있습니다.

앳홈은 18년도에 설립된 홈 라이프스타일 솔루션 기업으로, "고객의 생활에 행복을 제공한다"는 미션을 바탕으로 매년 빠르게 성장하고 있습니다. "고객의 숨겨진 문제를 해결하는 글로벌 No.1 브랜드 그룹"을 목표로, 공간의 가능성을 넓히는 가전 브랜드 미닉스, 프라이빗 에스테틱 솔루션 브랜드 톰, 단백질 식품 브랜드 프로티원 등 다양한 브랜드를 통해 고객들에게 행복과 만족을 선사하고 있습니다. 2024년에는 23년 대비 연 매출이 2배 이상 급성장했으며, 조직 규모도 100명 이상으로 확대되었습니다. 올해는 해외 진출을 통해 글로벌 시장으로 사업 영역을 확장해나갈 예정입니다. 앳홈 홈페이지 https://www.athomecorp.com 앳홈 채용사이트 https://career.athomecorp.com 앳홈 미디어 모음 https://www.athomecorp.com/news

Cupix is a global leader in spatial intelligence solutions for the built world. Founded with the mission to make reality capture more accessible and scalable, Cupix empowers builders, owners, and operators to gain complete visibility and documentation across every phase of the building lifecycle, from design and construction to operations and maintenance. By delivering a unified dataset within a powerful collaboration platform, Cupix enables teams to seamlessly share insights, track progress, and report directly within BIM. Our reality capture solutions are designed to be fully interoperable with industry-standard 3D formats, ensuring compatibility, accuracy, and smarter decision-making for every stakeholder.

Finally, an AI Platform You Can Trust. QueryPie empowers enterprises to safely operationalize AI. Built on proven Zero Trust principles, QueryPie connects MCPs, AI agents, and LLMs through a unified control layer — enabling secure, autonomous workflows across your cloud, systems, and tools. We provide both our own MCPs (DAC, SAC, KAC) and verified server integrations for enterprise platforms like Slack, GitHub, and AWS. With trusted infrastructure at its core, QueryPie ensures every AI action is governed, auditable, and aligned with your security policy. ついに実現－あなたの仕事を理解して、働くAI QueryPie AIは、企業がAIを安全に運用できる環境を提供します。 ゼロトラストの原則に基づき、MCP、AIエージェント、LLMを統合されたコントロールレイヤーで接続し、クラウド、システム、ツール全体にわたる安全で自律的なワークフローを実現します。 QueryPie AIは、自社開発のMCP（DAC、SAC、KAC）に加え、Slack、GitHub、AWSなど主要なエンタープライズツール向けに認証済みのMCPサーバー連携も提供しています。 信頼性の高いインフラを基盤に、すべてのAIアクションをガバナンス可能かつ監査対応とし、企業のセキュリティポリシーに準拠した運用を支援します。

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com

Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing. Learn more at http://www.standigm.com.

Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing. Learn more at http://www.standigm.com.

GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.

ServiceNow AI Research: shaping the future of work with AI At ServiceNow, we’re putting AI to work for people. As an AI-native company, ServiceNow sees agentic AI as a defining step in how enterprises will work with intelligent systems, moving from passive assistants to active digital coworkers. We believe AI should not just support the enterprise: it should act as an adaptive partner that can continuously learn, plan, and provide meaningful assistance in complex enterprise environments. Our goal is to help organizations across every industry transform through intelligent, scalable, and human-centered AI solutions, always guided by trust, responsibility, and impact. Who we are ServiceNow AI Research is a passionate team of scientists, researchers, and innovators dedicated to advancing the state of the art in enterprise AI. We bridge frontier research and real-world applications to ensure that every ServiceNow user benefits from intelligent, scalable, and trustworthy AI-driven experiences. Our mission aligns scientific excellence with business impact, unlocking the next generation of enterprise intelligence. Our commitment to ethics and open-source innovation As an AI-native company, responsibility is built into everything we do. At ServiceNow, we believe AI must be developed with fairness, transparency, and accountability, values that guide our work and commitment to building trustworthy enterprise AI. We are also dedicated to advancing AI through open-source contributions, fostering accessibility, collaboration, and continuous innovation within the global AI community.

Get the best coverage on startups and tech in Asia for free by signing up at techin.asia/3GQ8ao5 Tech in Asia is a media, events, and jobs platform for Asias tech communities. Visit www.techinasia.com/about to find out more, or reach out to our: - Editorial team: editors@techinasia.com - Business or Advertising team: www.techinasia.com/advertise - Tech hiring services: www.techinasia.com/jobs/recruitment Work with us at www.techinasia.com/advertise As of January 2024, Tech in Asia is a member of The Business Times (https://www.businesstimes.com.sg/).

‘기술과 사람이 만드는 더 나은 세상’ 카카오는 전문화된 인력, 기술력, 콘텐츠와 경쟁력 높은 모바일 트래픽을 바탕으로 글로벌 모바일 및 인터넷 시장에서 혁신적인 서비스를 제공하는 ‘모바일 라이프 플랫폼’ 기업입니다. 일상 생활을 둘러싼 모든 것을 연결하며, 누구나 일상의 혁신을 경험할 수 있도록 노력하고 있습니다. 1995년 설립된 다음커뮤니케이션과 2006년 설립된 카카오가 2014년 10월 1일 합병해 다음카카오로 출범했으며, 2015년 9월 23일 ‘카카오’로 사명을 변경해 모바일 시대를 대표하는 기업으로 나아가고 있습니다. 카카오는 지난 2010년 카카오톡 출시를 시작으로 국내 커뮤니케이션 패러다임을 바꿨으며, 페이나 모빌리티 등 다양한 서비스를 통해 이용자들의 생활 편의를 향상시켰습니다. 또한, 웹툰 및 미디어 영역 내에서 이용자들의 여가를 즐겁고 풍성하게 만들어 주고 있으며 헬스케어 및 AI 기술 투자, ESG 활동 등을 통해 이용자 삶의 새로운 혁신을 이끌며 사람과 세상을 이롭게 하는 카카오만의 가치를 만들어 내고 있습니다. 카카오 크루는 종종 이렇게 묻곤 합니다. "카카오스럽나요?" 앞으로도 우리는 더 나은 세상을 만들기 위해 카카오스러움에서 고민을 시작하고, 답을 찾을 것입니다. 카카오 영입 https://careers.kakao.com/ 카카오 문화 https://www.kakaocorp.com/page/about/kakaoCulture

Founded in 2020, Aidenlab is a leading South Korean marketing and beauty company that partners with top local and international brands. We specialize in helping brands expand globally and have a proven track record of setting new industry benchmarks.

At TriOar, our mission is to transform the future of antibody-based therapeutics. Led by a team of highly experienced scientists in the field, our work centers around developing next-generation antibody-drug conjugate (ADC) and immuno-oncology (IO) technologies to solve one of the biggest challenges in oncology: expanding the therapeutic index so that more patients can benefit from novel cancer therapies worldwide. If you share our passion for advancing oncology innovation, let’s connect and explore what we can achieve together.

웰로는 복잡한 정책 정보를 누구나 쉽고 당연하게 누리도록 만드는 Gov-Tech 혁신 기업입니다. 국민과 기업이 당연한 권리를 당연하게 누릴 수 있도록, 정책의 처음부터 끝까지 사용자 중심으로 변화시키고 있어요. 개인 맞춤형 정책 추천 서비스 Wello와 기업 데이터 기반 SaaS WelloBiz를 통해 정책 접근성을 높이고 있습니다.

Law&Company provide LawTalk service to solve information asymmetry and illegal legal broker of Korean legal market.

앳홈은 18년도에 설립된 홈 라이프스타일 솔루션 기업으로, "고객의 생활에 행복을 제공한다"는 미션을 바탕으로 매년 빠르게 성장하고 있습니다. "고객의 숨겨진 문제를 해결하는 글로벌 No.1 브랜드 그룹"을 목표로, 공간의 가능성을 넓히는 가전 브랜드 미닉스, 프라이빗 에스테틱 솔루션 브랜드 톰, 단백질 식품 브랜드 프로티원 등 다양한 브랜드를 통해 고객들에게 행복과 만족을 선사하고 있습니다. 2024년에는 23년 대비 연 매출이 2배 이상 급성장했으며, 조직 규모도 100명 이상으로 확대되었습니다. 올해는 해외 진출을 통해 글로벌 시장으로 사업 영역을 확장해나갈 예정입니다. 앳홈 홈페이지 https://www.athomecorp.com 앳홈 채용사이트 https://career.athomecorp.com 앳홈 미디어 모음 https://www.athomecorp.com/news